Apposite Capital’s acquisition of OrthoD Group from The Riverside Company


Apposite Capital, a private equity firm with an exclusive focus on healthcare, has teamed with management to acquire OrthoD Group from The Riverside Company.

OrthoD is a specialist manufacturer and distributor of medical products and implants for joint reconstruction, sport medicine, surgical products and infection control applications. Financial details have not been disclosed.

Apposite Capital sees significant potential in supporting management in further building OrthoD’s export channels and in further commercialising OrthoD’s sport medicine products. In conjunction with its investment, Apposite has introduced Oern Stuge, MD, as Non-Executive Chairman. Oern brings over 25 years’ experience in the medtech industry having held senior executive positions at Medtronic where he was a member of the Executive Committee & Operating Committee, and Abbott Laboratories.

Created in 1984, OrthoD is a UK based provider of specialist solutions for orthopaedic surgery. The company’s products range from bone cement management systems, wound drainage, fixation devices for knee and shoulder surgery and other specialist devices. The company has distribution channels in over 40 countries worldwide and employs over 100 people.

Osborne Clarke has advised the Senior Management team of OrthoD Group on its buyout funded by healthcare specialist Apposite Capital with a team led by Partner Mark Spinner (picture), supported by Senior Associate Tian Tang and Associate Kate Robinson.

Involved fees earner: Mark Spinner – Osborne Clarke; Tian Tang – Osborne Clarke; Kate Robinson – Osborne Clarke;

Law Firms: Osborne Clarke;

Clients: OrthoD Group;